Peripheral Vascular Diseases
Conditions
Keywords
Peripheral artery disease
Brief summary
The particular aim of this study is the comparison of the diagnostic results of MRA images upon application of Vasovist (gadofosveset), a contrast agent not yet available on the market, with the MRA images upon application of a conventional extracellular contrast agent. A catheter angiography, which will be performed as a routine diagnostic procedure for vascular diseases, will serve as an evaluation standard.
Detailed description
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany. Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Interventions
DRUGVasovist (BAY86-5283, MS-325)
All patients receive a single IV bolus injection of Vasovist at a dose of 0,03 mmol/kg BW at a flowrate of 0,5 mL/sec, followed by a saline flush of at least 30 mL
Sponsors
Bayer
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with a certain circulation disorder (aortoiliac disease Fontaine-stage IIb / IV) and an indication for the evaluation of the peripheral run-off arteries from the infrarenal aorta to the calves * Patients who are scheduled for X-ray angiography and magnetic resonance angiography (MRA) of the arteries mentioned above * Patients who have had a contrast-enhanced MRA examination of the arteries mentioned above using a standard extracellular contrast agent performed within 1 - 7 days prior to the study MRA examination
Exclusion criteria
* Less than 18 years of age * Women who are pregnant, breast feeding or who are of childbearing potential and have not had a negative urine pregnancy test the same day as the study MRA examination * Requiring immediate therapy for their vascular disease or in whom conduct of all three angiographic procedures is not possible * Not being able to remain lying down for at least 45 - 60 min * Patients with a history of serious allergic reactions to any allergen including drugs and contrast agents or with a history of sickle cell disease or other hemolytic anemia * Having any contraindication to magnetic resonance imaging (MRI) examination or specifically for MRA (e.g. pacemaker, recent wound clips, and severe claustrophobia)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Diagnostic potential of Vasovist enhanced MRA | Imaging after baseline visit, before and after Vasovist injection |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of the quantitative assessment and the qualitative assessment of arterial stenosis/disease as compared to X-ray angiography | After imaging |
| Quantitative assessment of vessel enhancement | After imaging |
| Qualitative assessment of disease | After imaging |
| Qualitative assessment of plaque morphology | After imaging |
| Evaluation of quality of vascular anatomy and delineation of vessel wall, venous enhancement and diagnostic potential of venous enhancement | After imaging |
Countries
Argentina, Austria, Brazil, Germany, Mexico, Switzerland
Outcome results
None listed